Debu Tripathy, MD | Authors

June 17, 2021

Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

March 29, 2021

Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.

March 09, 2021

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

July 03, 2019

Debu Tripathy, MD, of the Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, was an investigator in the phase III MONALEESA-7 trial. The purpose of the study was to examine how endocrine therapy, in combination with a cyclin-dependent kinase inhibitor, affects progression-free survival and overall survival in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

February 21, 2019

Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.

June 06, 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline BRCA 1/2 mutations during the 2017 ASCO Annual Meeting.